Incannex Healthcare (IXHL) Capital Expenditures (2023 - 2026)

Incannex Healthcare (IXHL) posted Capital Expenditures of $5000.0 for Q1 2026, up 25.0% sequentially from $4000.0 in Q4 2025.

Incannex Healthcare (IXHL) Capital Expenditures (2023 - 2026) Analysis & Trends

Incannex Healthcare has reported Capital Expenditures for 4 years, with the latest figure at $5000.0 in Q1 2026.

Quarterly Capital Expenditures changed N/A year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11000.0 (down 80.36% YoY) and the FY2025 annual result came in at $8000.0, down 97.11% from the prior year.
Capital Expenditures grew to $5000.0 in Q1 2026 per IXHL's latest filing, from $4000.0 in the prior quarter.
Over five years, Capital Expenditures peaked at $221000.0 in Q3 2023 and troughed at -$6000.0 in Q1 2024.
A 4-year average of $54555.6 and a median of $5000.0 in 2026 frame the typical range for Capital Expenditures.
The widest YoY moves for Capital Expenditures: up 98.25% in 2024, down 118.75% in 2024.
Over 4 years, Capital Expenditures stood at $59000.0 in 2023, then plunged by 94.92% to $3000.0 in 2024, then jumped by 33.33% to $4000.0 in 2025, then climbed by 25.0% to $5000.0 in 2026.
According to Business Quant data, Capital Expenditures over the past three periods registered $5000.0, $4000.0, and $2000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Capex (Qtr)
1	Haleon	44.51 Bn	43.55 Bn	-	-
2	Teva Pharmaceutical Industries	43.52 Bn	39.86 Bn	2.15 Bn	104.00 Mn
3	Zoetis	32.43 Bn	30.75 Bn	1.05 Bn	117.00 Mn
4	Takeda Pharmaceutical	28.63 Bn	22.83 Bn	5.10 Bn	-337.60 Mn
5	United Therapeutics	21.87 Bn	19.21 Bn	683.80 Mn	108.00 Mn
6	Viatris	18.98 Bn	18.09 Bn	1.46 Bn	52.80 Mn
7	Neurocrine Biosciences	15.43 Bn	15.04 Bn	935.80 Mn	7.80 Mn
8	Elanco Animal Health	12.02 Bn	11.49 Bn	798.00 Mn	33.00 Mn
9	Dr Reddys Laboratories	10.14 Bn	9.98 Bn	-	-
10	Incannex Healthcare	44.39 Mn	44.39 Mn	-	5,000.00

Download Data